S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:TNXP

Tonix Pharmaceuticals News Headlines

$0.91
-0.05 (-5.21 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.88
Now: $0.91
$0.95
50-Day Range
$0.55
MA: $0.67
$1.00
52-Week Range
$0.39
Now: $0.91
$2.46
Volume29.92 million shs
Average Volume58.90 million shs
Market Capitalization$195.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53

Headlines

Tonix Pharmaceuticals (NASDAQ TNXP) News Headlines Today

Source:
SourceHeadline
Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune ConditionsTonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions
finance.yahoo.com - January 14 at 4:33 PM
Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq RulesTonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - January 13 at 8:28 PM
5 Penny Stocks to Watch If Biotech Stocks Are Your Focus in January 20215 Penny Stocks to Watch If Biotech Stocks Are Your Focus in January 2021
marketwatch.com - January 13 at 3:21 PM
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up to $0.93Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up to $0.93
americanbankingnews.com - January 13 at 11:54 AM
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 13.5%Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 13.5%
americanbankingnews.com - January 12 at 7:14 PM
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq RulesTonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules
finance.yahoo.com - January 11 at 6:10 PM
Tonix Pharmaceuticals prices $40M equity offeringTonix Pharmaceuticals prices $40M equity offering
seekingalpha.com - January 11 at 1:52 PM
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7%Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7%
americanbankingnews.com - January 7 at 12:10 AM
Tonix Pharmaceuticals to Participate in Upcoming January ConferencesTonix Pharmaceuticals to Participate in Upcoming January Conferences
benzinga.com - January 5 at 4:32 PM
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up to $0.72Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up to $0.72
americanbankingnews.com - January 5 at 10:58 AM
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant RejectionTonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
finance.yahoo.com - January 5 at 8:54 AM
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 5.9%Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 5.9%
americanbankingnews.com - January 4 at 9:34 PM
Tonix Pharmaceuticals (NASDAQ:TNXP)  Shares Down 6.2% Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 6.2%
americanbankingnews.com - December 29 at 7:54 PM
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up to $0.66Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up to $0.66
americanbankingnews.com - December 24 at 11:12 AM
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 15.5%Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 15.5%
americanbankingnews.com - December 23 at 7:36 PM
Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)
finance.yahoo.com - December 22 at 8:43 AM
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development PlansTonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans
finance.yahoo.com - December 21 at 8:05 AM
TNXP: Positive Results for TNX-102 SL in Phase 3 RELIEF Trial…TNXP: Positive Results for TNX-102 SL in Phase 3 RELIEF Trial…
finance.yahoo.com - December 15 at 1:26 PM
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in FibromyalgiaTonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
benzinga.com - December 7 at 7:15 AM
Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox VirusVaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus
finance.yahoo.com - December 4 at 6:53 PM
TNXP: Animal Data for SARS-CoV-2 Vaccine Candidate Shows Robust Immune Response…TNXP: Animal Data for SARS-CoV-2 Vaccine Candidate Shows Robust Immune Response…
finance.yahoo.com - November 30 at 1:30 PM
Tonix Pharmas COVID-19 vaccine candidate shows encouraging preclinical actionTonix Pharma's COVID-19 vaccine candidate shows encouraging preclinical action
seekingalpha.com - November 16 at 12:19 PM
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human PrimatesTonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
finance.yahoo.com - November 16 at 7:18 AM
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development SummitTonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit
finance.yahoo.com - November 12 at 6:54 PM
Tonix Pharmaceuticals to Present at the virtual Fall Investor Summit on November 16th-18thTonix Pharmaceuticals to Present at the virtual Fall Investor Summit on November 16th-18th
finance.yahoo.com - November 12 at 8:52 AM
Tonix Pharmaceuticals to Participate in Upcoming November ConferencesTonix Pharmaceuticals to Participate in Upcoming November Conferences
finance.yahoo.com - November 11 at 7:48 AM
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development SummitTonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
finance.yahoo.com - November 9 at 6:24 PM
Tonix Pharmaceuticals EPS beats by $0.02Tonix Pharmaceuticals EPS beats by $0.02
seekingalpha.com - November 9 at 1:24 PM
Tonix Provides Updates For Fibromyalgia, And Other News: The Good, Bad And Ugly Of BiopharmaTonix Provides Updates For Fibromyalgia, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - October 28 at 2:15 AM
Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and TherapeuticsTonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
finance.yahoo.com - October 22 at 3:49 PM
Tonix Pharma launches observational study facilitating development of tailored COVID-19 vaccines and therapeuticsTonix Pharma launches observational study facilitating development of tailored COVID-19 vaccines and therapeutics
seekingalpha.com - October 15 at 10:34 AM
Tonix Pharmaceuticals CEO on Vaccine Progress (Podcast)Tonix Pharmaceuticals CEO on Vaccine Progress (Podcast)
bloomberg.com - October 14 at 2:27 AM
Tonix Pharma to conclude TNX-102 SL late-stage study with currently enrolled chronic disorder patientsTonix Pharma to conclude TNX-102 SL late-stage study with currently enrolled chronic disorder patients
seekingalpha.com - September 29 at 6:25 PM
Tonix Pharma to conclude TNX-102 late-stage study with currently enrolled chronic disorder patientsTonix Pharma to conclude TNX-102 late-stage study with currently enrolled chronic disorder patients
seekingalpha.com - September 29 at 6:25 PM
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
finance.yahoo.com - September 17 at 2:14 PM
Enrollment underway in Tonix Pharmas observational study in COVID-19Enrollment underway in Tonix Pharma's observational study in COVID-19
seekingalpha.com - September 15 at 1:07 PM
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
finance.yahoo.com - September 15 at 1:07 PM
TNXP: Interim Analysis for Phase 3 RELIEF Trial in Sep. 2020; Preclinical data for TNX-1800 in 4Q20…TNXP: Interim Analysis for Phase 3 RELIEF Trial in Sep. 2020; Preclinical data for TNX-1800 in 4Q20…
finance.yahoo.com - September 3 at 5:47 PM
Enrollment underway in Tonix Pharmas Phase 3 RALLY study for fibromyalgiaEnrollment underway in Tonix Pharma's Phase 3 RALLY study for fibromyalgia
seekingalpha.com - September 3 at 12:47 PM
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of FibromyalgiaTonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia
finance.yahoo.com - September 3 at 12:47 PM
Insider Buys Tonix Pharmaceuticals's StockInsider Buys Tonix Pharmaceuticals's Stock
finance.yahoo.com - September 1 at 6:07 PM
Insider Buys Tonix Pharmaceuticalss StockInsider Buys Tonix Pharmaceuticals's Stock
benzinga.com - September 1 at 1:07 PM
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor ConferencesTonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences
finance.yahoo.com - August 27 at 12:29 PM
With Key Data Nearing, Tonix Looks to Spotlight Robust Pipeline In Immunology And CNS TherapeuticsWith Key Data Nearing, Tonix Looks to Spotlight Robust Pipeline In Immunology And CNS Therapeutics
finance.yahoo.com - August 26 at 10:38 AM
Insider Buys Tonix Pharmaceuticals SharesInsider Buys Tonix Pharmaceuticals Shares
benzinga.com - August 24 at 12:23 PM
Insider Buys Tonix Pharmaceuticals StockInsider Buys Tonix Pharmaceuticals Stock
benzinga.com - August 19 at 12:46 PM
Tonix Pharmaceuticals Holding Corp (TNXP) CEO Seth Lederman Bought $54,600 of SharesTonix Pharmaceuticals Holding Corp (TNXP) CEO Seth Lederman Bought $54,600 of Shares
finance.yahoo.com - August 17 at 1:16 PM
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational HighlightsTonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
finance.yahoo.com - August 10 at 1:12 PM
Tonix Pharma on go with study of TNX-102 SL in alcohol use disorderTonix Pharma on go with study of TNX-102 SL in alcohol use disorder
seekingalpha.com - August 6 at 1:07 PM
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use DisorderTonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
finance.yahoo.com - August 6 at 1:07 PM
This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.